Last reviewed · How we verify
NCT06989541: ICART
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
trial testing Immune Globulin Intravenous (Human), 10% in Hypogammaglobulinemia, Acquired in 30 participants. Currently enrolling.
1 May 2027
Quick facts
| Lead sponsor | University of Alberta |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 June 2025 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Immune Globulin Intravenous (Human), 10%
- Immune Globulin Subcutaneous (Human), 20% Solution — full drug profile →
Conditions studied
- Hypogammaglobulinemia, Acquired — all drugs for Hypogammaglobulinemia, Acquired →
Sponsor
University of Alberta
Who can join
18 and older, any sex, with Hypogammaglobulinemia, Acquired. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells. These cells are designed to look for a marker called CD19, which is found on both cancer cells and healthy B cells (a type of white blood cell). Because of this, CAR T cells can also destroy healthy B cells. This can lead to a strong drop in B cells and cause a condition called hypogammaglobulinemia (HGG), which makes it harder for the body to fight infections. Serious infections are common in people treated with CAR T cells and are a major reason for death that is not caused by the return of cancer. To help prevent infections, patients with HGG often get immunoglobulin replacement therapy (IRT), which gives them the antibodies they need. This treatment can be given through a vein (IVIG) or under the skin (SCIG). The goal of this project is to study how often these patients get bacterial infections, how they feel about their quality of life and treatment, and what side effects they may have when treated with IVIG or SCIG after CAR T-cell therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06989541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immune Globulin Intravenous (Human), 10%
Trials testing the same drug.
- NCT01412385 — Immune Globulin Subcutaenous (Human), 20% · Phase 2, PHASE3 · completed
- NCT00546871 — Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects · Phase 2, PHASE3 · completed
- NCT00157079 — Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disord · Phase 3 · completed
Other recruiting trials for Hypogammaglobulinemia, Acquired
Currently open trials in the same condition.
- NCT06976476 — Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia · Phase 2 · recruiting
Other University of Alberta trials
Trials by the same sponsor.
- NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
- NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
- NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06989541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alberta
- Last refreshed: 3 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06989541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing